Goldman Sachs Group Reiterates “Buy” Rating for Qiagen (NYSE:QGEN)

Goldman Sachs Group restated their buy rating on shares of Qiagen (NYSE:QGEN) in a report published on Friday, Borsen Zeitung reports.

A number of other equities analysts also recently issued reports on the company. Zacks Investment Research upgraded Qiagen from a sell rating to a buy rating and set a $45.00 price objective for the company in a report on Tuesday, April 16th. UBS Group initiated coverage on Qiagen in a report on Friday, March 15th. They issued a neutral rating and a $42.00 price objective for the company. Deutsche Bank reiterated a buy rating on shares of Qiagen in a report on Friday, April 12th. Finally, Wolfe Research initiated coverage on Qiagen in a report on Thursday, May 30th. They issued a peer perform rating for the company. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Qiagen currently has a consensus rating of Buy and a consensus target price of $42.00.

Shares of QGEN stock opened at $40.68 on Friday. The business has a fifty day simple moving average of $38.46. Qiagen has a 52 week low of $32.33 and a 52 week high of $41.55. The stock has a market capitalization of $9.18 billion, a price-to-earnings ratio of 30.36, a price-to-earnings-growth ratio of 2.44 and a beta of 0.84. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. The business had revenue of $348.70 million during the quarter, compared to the consensus estimate of $351.68 million. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.26 earnings per share. As a group, research analysts predict that Qiagen will post 1.43 EPS for the current year.

Several large investors have recently modified their holdings of QGEN. BB&T Securities LLC lifted its holdings in shares of Qiagen by 7.0% during the 4th quarter. BB&T Securities LLC now owns 7,527 shares of the company’s stock worth $259,000 after acquiring an additional 490 shares during the period. Lindbrook Capital LLC bought a new position in shares of Qiagen during the 4th quarter worth about $25,000. Toronto Dominion Bank lifted its holdings in shares of Qiagen by 71.9% during the 4th quarter. Toronto Dominion Bank now owns 27,004 shares of the company’s stock worth $918,000 after acquiring an additional 11,294 shares during the period. LPL Financial LLC lifted its holdings in shares of Qiagen by 11.4% during the 4th quarter. LPL Financial LLC now owns 10,932 shares of the company’s stock worth $377,000 after acquiring an additional 1,123 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Qiagen by 38.2% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,528 shares of the company’s stock worth $119,000 after acquiring an additional 976 shares during the period. Hedge funds and other institutional investors own 63.22% of the company’s stock.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: What are the FAANG Stocks?

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.